Nivolumab Plus Cabozantinib Tops Sunitinib for Renal Cell Carcinoma
WEDNESDAY, March 3, 2021 -- For patients with previously untreated advanced renal cell carcinoma, nivolumab plus cabozantinib has significant benefits over sunitinib with respect to progression-free and overall survival, according to a study...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Carcinoma | Kidney Cancer | Pharmaceuticals | Renal Cell Carcinoma | Study